ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Sells $334,552.50 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) COO Brendan Teehan sold 14,869 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $22.50, for a total transaction of $334,552.50. Following the completion of the transaction, the chief operating officer now directly owns 24,356 shares of the company’s stock, valued at $548,010. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Brendan Teehan also recently made the following trade(s):

• On Monday, May 1st, Brendan Teehan sold 548 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $21.18, for a total transaction of $11,606.64.
• On Thursday, April 6th, Brendan Teehan sold 1,751 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $18.16, for a total transaction of $31,798.16.
• On Friday, February 24th, Brendan Teehan sold 461 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $18.78, for a total value of $8,657.58.

ACADIA Pharmaceuticals Stock Up 4.8 %

ACADIA Pharmaceuticals stock opened at $24.31 on Friday. ACADIA Pharmaceuticals Inc. has a twelve month low of $12.24 and a twelve month high of $24.32. The business has a fifty day moving average of $20.04 and a two-hundred day moving average of $18.22. The firm has a market cap of $3.95 billion, a P/E ratio of -26.71 and a beta of 0.54.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last issued its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.06). ACADIA Pharmaceuticals had a negative return on equity of 35.70% and a negative net margin of 28.05%. The company had revenue of $118.46 million for the quarter, compared to analysts’ expectations of $120.29 million. During the same quarter last year, the company earned ($0.70) earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Equities analysts expect that ACADIA Pharmaceuticals Inc. will post -0.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ACAD. Bain Capital Life Sciences Investors LLC boosted its stake in ACADIA Pharmaceuticals by 1.7% in the third quarter. Bain Capital Life Sciences Investors LLC now owns 610,523 shares of the biopharmaceutical company’s stock valued at $9,988,000 after acquiring an additional 10,000 shares in the last quarter. Hohimer Wealth Management LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 26.5% during the 4th quarter. Hohimer Wealth Management LLC now owns 20,265 shares of the biopharmaceutical company’s stock valued at $323,000 after purchasing an additional 4,250 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of ACADIA Pharmaceuticals by 1.1% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 200,032 shares of the biopharmaceutical company’s stock valued at $3,273,000 after purchasing an additional 2,117 shares during the last quarter. Gibson Wealth Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 6,200.0% in the 4th quarter. Gibson Wealth Advisors LLC now owns 6,300 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 6,200 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in ACADIA Pharmaceuticals by 268.9% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 102,825 shares of the biopharmaceutical company’s stock worth $1,682,000 after buying an additional 74,952 shares during the last quarter. Hedge funds and other institutional investors own 92.79% of the company’s stock.

Analysts Set New Price Targets

ACAD has been the subject of several analyst reports. Guggenheim raised their price objective on ACADIA Pharmaceuticals from $22.00 to $25.00 in a research note on Tuesday, March 14th. Credit Suisse Group boosted their price objective on shares of ACADIA Pharmaceuticals from $93.00 to $95.00 in a research report on Friday, April 28th. Citigroup lifted their price target on shares of ACADIA Pharmaceuticals from $21.00 to $21.60 in a research note on Tuesday, May 9th. Jefferies Financial Group increased their price objective on shares of ACADIA Pharmaceuticals from $10.00 to $15.00 in a research report on Tuesday, March 14th. Finally, StockNews.com started coverage on shares of ACADIA Pharmaceuticals in a research note on Thursday. They issued a “buy” rating for the company. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $25.40.

ACADIA Pharmaceuticals Company Profile

(Get Rating)

ACADIA Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.